Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study

Hans-Dirk Düngen1,14*, Verena Tscholl2†, Danilo Obradovic1,14, Sara Radenovic1,14, Dragan Matić3, Lindy Musial Bright4, Elvis Tahirovic1,14, Almuth Marx4, Simone Inkrot1,5, Djawid Hashemi1,14, Jovan Veskovic1,14, Svetlana Apostolovic6, Stephan von Haehling7,8, Wolfram Doehner9, Natasa Cvetinovic10, Mitja Lainscak11,12, Burkert Pieske1,14, Frank Edelmann1,14, Tobias Trippel1,14† and Goran Loncar10,13‡

1Department of Cardiology, Charité – Universitätsmedizin Berlin, Campus Virchow Klinikum, Medizinische Klinik m. S. Kardiologie, Augustenburger Platz 1 1D-13353, Berlin, Germany; 2Department of Cardiology, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany; 3Emergency Department, Clinic for Cardiology, Clinical Centre of Serbia, Belgrade, Serbia; 4Marx-Statistics, Nuremberg, Germany; 5Department of Cardiology, Waikato Hospital, Hamilton, New Zealand; 6Clinical for Cardiovascular Diseases, Clinical Center Niš, Niš, Serbia; 7Applied Cachexia Research, Department of Cardiology, Charité Medical School, Berlin, Germany; 8Division of Innovative Trials, University Medical Center Göttingen, Göttingen, Germany; 9Center for Stroke Research, Charité – Universitätsmedizin Berlin, Berlin, Germany; 10Department of Cardiology, Clinical Hospital Zvezdara, Belgrade, Serbia; 11Department of Cardiology, General Hospital Celje, Celje, Slovenia; 12Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; 13School of Medicine, University of Belgrade, Belgrade, Serbia; 14German Centre for Cardiovascular Research DZHK, Partner Site Berlin, Berlin, Germany

Abstract

Aims In heart failure, various biomarkers are established for diagnosis and risk stratification; however, little is known about the relevance of serial measurements during an episode worsening heart failure (WHF). This study sought to investigate the trajectory of natriuretic peptides and multiple novel biomarkers during hospitalization for WHF and to determine the best time point to predict outcome.

Methods and results MOLITOR (Impact of Therapy Optimisation on the Level of Biomarkers in Patients with Acute and Decompensated Chronic Heart Failure) was an eight-centre prospective study of 164 patients hospitalized with a primary diagnosis of WHF. C-terminal fragment of pre-pro-vasopressin (copeptin), N-terminal pro-B-type natriuretic peptide (NT-proBNP), mid-regional pro-atrial natriuretic peptide (MR-proANP), mid-regional pro-adrenomedullin (MR-proADM), and C-terminal pro-endothelin-1 (CT-proET1) were measured on admission, after 24, 48, and 72 h, and every 72 h thereafter, at discharge and follow-up visits. Their performance to predict all-cause mortality and rehospitalization at 90 days was compared. All biomarkers decreased during recompensation (P < 0.05) except MR-proADM. Copeptin at admission was the best predictor of 90 day mortality or rehospitalization (χ² = 16.63, C-index = 0.724, P < 0.001), followed by NT-proBNP (χ² = 10.53, C-index = 0.646, P = 0.001), MR-proADM (χ² = 9.29, C-index = 0.686, P = 0.002), MR-proANP (χ² = 8.75, C-index = 0.631, P = 0.003), and CT-proET1 (χ² = 6.60, C-index = 0.64, P = 0.010). Re-measurement of copeptin at 72 h and of NT-proBNP at 48 h increased prognostic value (χ² = 23.48, C-index = 0.718, P = 0.00001; χ² = 14.23, C-index = 0.650, P = 0.00081, respectively).

Conclusions This largest sample of serial measurements of multiple biomarkers in WHF found copeptin at admission with re-measurement at 72 h to be the best predictor of 90 day mortality and rehospitalization.

Keywords Worsening heart failure; Biomarker trajectory; Serial measurement; Copeptin

Received: 23 June 2017; Revised: 10 September 2017; Accepted: 27 September 2017

*Correspondence to: Hans-Dirk Düngen, Department of Cardiology, Charité – Universitätsmedizin Berlin, Campus Virchow Klinikum, Medizinische Klinik m. S. Kardiologie, Augustenburger Platz 1, D-13353 Berlin, Germany. Tel: +49 30 450 665 471; Fax: +49 30 450 7565 471. Email: hans-dirk.duengen@charite.de
Clinical Trial Registration: http://clinicaltrials.gov. Unique identifier: NCT01501981
Hans-Dirk Düngen and Verena Tscholl share the first authorship.
†Tobias Trippel and Goran Loncar share the last authorship.

© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Introduction

Approximately 14 million people in the European Union have been diagnosed with heart failure (HF). Worsening heart failure (WHF) is the leading cause of hospital admissions worldwide and is associated with high morbidity and mortality. None of the prospective clinical trials have shown that any therapy started during hospitalization can improve mortality and risk of rehospitalization in these patients. Therefore, guidelines recommend mainly symptomatic therapy. To which degree WHF patients respond to the therapy ranges from uncomplicated recompensation to prolonged hospital stay with early readmission or even fatal outcome. Better prognostic assessment may help clinicians in identification of patients who should ‘move to the front of the line’ with respect to immediate therapeutic interventions.

The measurement of natriuretic peptides [i.e. N-terminal pro-B-type natriuretic peptide (NT-proBNP)] is frequently used to evaluate patients whose diagnosis of HF is uncertain. During hospitalization, natriuretic peptides are thought to be helpful in risk stratification, and a fall in peptide levels correlate with a better prognosis. Recently, other candidate peptides, such as mid-regional pro-adrenomedullin (MR-proADM) and copeptin, were found to add prognostic value. Copeptin is C-terminal fragment of pre-pro-vasopressin. Unlike vasopressin, it is stable and can be easily measured. Adrenomedullin is a vasodilatory peptide with hypotensive effects, and its levels are elevated in HF patients. However, since its plasma half-life is only around 22 min, proADM is used as a trustworthy biomarker. Endothelin-1 is a vasoconstrictor peptide, which is produced by vascular tissue, and increases blood pressure. HF patients are often found with elevated levels of ET-1, as a result of neurohormonal activation. Due to its instability, the C-terminal portion of pro-endothelin-1, which is much more stable, is commonly being measured. Atrial natriuretic peptide (ANP) is released from the atria as a response to elevated intra-atrial pressure and wall stretch, but its concentrations are difficult to be measured due to its short half-life (2–5 min). However, ANP’s prohormone (proANP) has a longer half-life, and its mid-region (MR-proANP) can be detected easily.

Further, serial biomarker measurement in HF management has received growing interest for outcome prediction. However, most authors assessed biomarkers only on admission and pointed out rare time points to re-measure, for example, prior to discharge. Indeed, little is known about the exact trajectory of biomarkers during an episode of decompensation, and there has not been a comparison of the prognostic performance of serial measurements.

The primary aim of this study was to determine the performance of serial in-hospital measurements of natriuretic peptides and multiple novel biomarkers to predict outcome in WHF patients.

Methods

MOLITOR (Impact of Therapy Optimisation on the Level of Biomarkers in Patients with Acute and Decompensated Chronic Heart Failure) was an eight-centre prospective study of 164 patients presenting to the emergency department with a primary diagnosis of WHF. The study is registered under http://clinicaltrials.gov (NCT01501981), sponsored by Charité – Universitätsmedizin Berlin, and financed by an unrestricted grant by BRAHMS AG (Neuendorfstr. 25, 16761 Hennigsdorf, Germany).

Study population

The institutional review boards of all participating centres approved the study, and all patients gave their written informed consent. In order to be considered as eligible, patients had to have signs and symptoms of HF with dyspnoea at rest or with minimal exertion (New York Heart Association (NYHA) class III and IV) and pulmonary congestion on physical examination or chest X-ray. Patients were excluded if they had an alternative diagnosis that could account for the patient’s HF symptoms, for example, significant pulmonary disease (history of oral daily steroid dependency, history of CO2 retention, or need for intubation for acute exacerbation); had suspected acute myocardial infarction, cardiogenic shock, sepsis or active infection requiring i.v. antimicrobial treatment; had significant arrhythmias (ventricular tachycardia, bradyarrhythmias with ventricular rate < 45 b.p.m., or atrial fibrillation/flutter with ventricular response of >150 b.p.m.), significant kidney disease with current or planned haemofiltration or dialysis, acute myocarditis, hypertrophic obstructive, restrictive, or constrictive cardiomyopathy; or were younger than 18 years. The primary endpoint was the best time point to predict all-cause death or rehospitalization within 90 days.

Measurement of biomarkers

All blood samples were taken at admission, after 24, 48, and 72 h, and every 72 h thereafter, at discharge and at regular follow-up visits. Blood samples were collected in ethylenediaminetetraacetic acid (plasma separated within 60 min by centrifugation) and serum tubes and stored at −70°C in plastic freezer vials. NT-proBNP (Elecys 2010 analyzer, Roche Diagnostics, Indianapolis, IN) and copeptin and MR-proANP (both on the KRYPTOR system) were measured centrally with the support of BRAHMS/Thermo Fisher, Germany. MR-proADM was measured using an automated sandwich chemiluminescence immunoassay on the KRYPTOR system, as previously described. For MR-proADM, the limit of
Statistical analysis

Statistical analysis was performed by an independent trial biometrician in accordance with a pre-defined statistical analysis plan. Descriptives of variables are expressed as mean ± standard deviation or median (Quartiles 1 and 3) for highly skewed variables, and n (%) for categorical variables. Values of biomarkers were log10 transformed prior to inclusion into regression models. Serial changes in biomarker levels during treatment optimization were assessed by Student t-tests for paired samples on log10-transformed data. Spearman rank correlation coefficients were calculated to assess the relationship between investigated biomarkers. For the primary endpoint all-cause mortality/hospitalizations at 90 days, Cox regression models were built for each biomarker for baseline values (univariate). To determine the diagnostic accuracy of serum biomarker levels for the prediction of all-cause mortality/hospitalization, receiver operating characteristic plots were analysed, and areas under the curve were calculated for all analytes. Areas under the curve were compared according to the method by Blanche. The whole study population of 164 patients with WHF was then stratified according to tertiles of copeptin and NT-proBNP. Using the tertile approach, we computed Kaplan–Meier estimates of event-free survival probabilities, and log-rank tests were performed to compare survival curves between the groups. The time-dependent Cox model was used to test whether there is a significant added value of the follow-up measurements of biomarkers concentration on top of those obtained on admission.20 We defined the significance level 0.05 for all tests. R 3.0.2 software was used for all statistical analysis.

Results

Description of general population

A total of 164 patients (mean age 69, 70% male, mean left ventricular ejection fraction 34%, 76% in NYHA class III) were enrolled at eight sites in Germany, Serbia, and Slovenia. Table 1 displays demographic and clinical characteristics. Mean length of stay was 7 days. At 90 days, 18 (10.6%) patients had died and 24 (14.1%) were rehospitalized. Eight patients died during index hospitalization.

Serial in-hospital changes of biomarkers

All biomarkers decreased significantly from admission to discharge (P < 0.05) except MR-proADM (Table 2). All baseline biomarker levels correlated significantly, with a high correlation found for the natriuretic peptides and between MR-proADM and C-terminal pro-endothelin-1 (CT-proET1; Table 3).

Prognostic value of biomarker levels at baseline

The prognostic value for all-cause mortality/hospitalization at 90 days is presented with the receiver operating characteristic curves in Figure 1. All biomarkers at admission, except for CT-proET1, were significant univariate outcome predictors (Table 4). At baseline, copeptin was the strongest predictor (χ² = 16.63, C-index = 0.724, P < 0.001), followed by NT-proBNP (χ² = 10.53, C-index = 0.646, P = 0.001). Similarly, copeptin showed a trend (P = 0.0565) towards a 19% improvement of net reclassification for patients at the highest risk of 90 day mortality or rehospitalization (95% confidence interval [−0.5, 39.1]). Defining a copeptin threshold of 37.2 pmol/L at baseline, the positive and negative predictive values of all-cause death/hospitalization were 45.3% and 89%, respectively. Likewise, sensitivity and specificity for this cut-off were 72.5% and 71.8%. Addition of baseline copeptin levels to baseline NT-proBNP levels significantly improved its prognostic performance for 90 day outcome [model likelihood ratio (LR) χ² = 17.80, C-index = 0.688, P = 0.004], unlike in the addition of other novel cardiac biomarkers including MR-proADM (data not shown). Figure 2 shows Kaplan–Meier curves for three groups of patients stratified according to the tertiles plasma concentrations of copeptin (Figure 2A) and NT-proBNP (Figure 2B). The highest tertile of baseline copeptin and NT-proBNP was related with the worst prognosis at 3 months’ follow-up (Figure 3).

Prognostic performance of serial in-hospital measurements of biomarkers

The best time point for re-measurement of copeptin was 72 h after admission, and then its predictive value was increased (copeptin χ² = 23.48, C-index = 0.718, P = 0.00001). Patients with levels <50 pmol/L at admission and at 72 h had the best prognosis, while patients with low levels at admission that increased after 72 h had an even worse prognosis than had patients with elevated levels at admission (>50 pmol/L) (see Figure 4). Patients with persistently elevated copeptin during the first 72 h after initial in-hospital evaluation had the worst prognosis at 3 months’ follow-up. With the unadjusted adapted time-dependent Cox model, we found a
Table 1  Patient characteristics at baseline according to events (all-cause mortality/hospitalization) for the entire cohort (n = 164)

|                          | All patients (n = 164) | Event free (n = 124) | Dead or rehospitalized (n = 40) | P-value* |
|--------------------------|------------------------|----------------------|-------------------------------|----------|
| **Demographics**         |                        |                      |                               |          |
| Age, years, mean (SD)    | 68.3 (10)              | 67.9 (10.2)          | 69.5 (9.4)                    | 0.361    |
| Male sex, n (%)          | 116 (70.7)             | 89 (71.8)            | 27 (67.5)                     | 0.751    |
| **Clinical**             |                        |                      |                               |          |
| BMI                       |                        |                      |                               |          |
| Systolic blood pressure, mean (SD) | 136.7 (26.1) | 136.9 (25) | 135.8 (29.5) | 0.807    |
| Diastolic blood pressure, mean (SD) | 82.3 (14.8)  | 83.6 (14.8) | 78.5 (14.3) | 0.055    |
| Heart rate, mean (SD)    | 91.8 (20.9)            | 93.3 (20.8)          | 87.1 (20.6)                   | 0.101    |
| Heart rate in patients with sinus rhythm, mean (SD) | 88.9 (18.9) | 90.1 (18.1) | 83.8 (21.7) | 0.203    |
| Heart rate in patients with atrial fibr, mean (SD) | 97.3 (21.5) | 100.1 (21.7) | 90.9 (20.2) | 0.111    |
| Pulmonary rales, n (%)   | 161 (98.2)             | 122 (98.4)           | 39 (97.5)                     | 1.000    |
| Peripheral oedema, n (%) | 121 (73.8)             | 89 (71.8)            | 32 (80)                       | 0.411    |
| NYHA class III, n (%)    | 124 (75.6)             | 98 (79)              | 26 (65)                       | 0.113    |
| NYHA class IV, n (%)     | 40 (24.4)              | 26 (21)              | 14 (35)                       | 0.113    |
| Atrial fibrillation, n (%)| 65 (39.6)             | 45 (36.3)            | 20 (50)                       | 0.175    |
| LVEF (%), mean (SD)      | 33.9 (12.5)            | 34.3 (12.6)          | 32.6 (12.2)                   | 0.451    |
| LVEDD (mm), mean (SD)    | 61.9 (11.3)            | 60.8 (11.5)          | 65.3 (10.3)                   | 0.031    |
| Intraventricular septum diameter, mean (SD) | 9.9 (3.3)     | 9.9 (3.5)            | 10.1 (2.6)                    | 0.089    |
| E/e’, mean (SD)          | 14.6 (21.7)            | 14 (18.9)            | 16.3 (28.3)                   | 0.670    |
| Pacemaker, n (%)         | 5 (3)                  | 2 (1.6)              | 3 (7.5)                       | 0.176    |
| ICD/CRT, n (%)           | 9 (5.5)                | 5 (4)                | 4 (10)                        | 0.297    |
| **Co-morbidities**       |                        |                      |                               |          |
| Diabetes mellitus, n (%)  | 65 (39.6)             | 49 (35.9)            | 16 (40)                       | 1.000    |
| Hypertension, n (%)      | 137 (84.6)             | 102 (83.6)           | 35 (87.5)                     | 0.734    |
| GFR < 60, n (%)          | 84 (51.9)              | 58 (47.5)            | 26 (65)                       | 0.063    |
| COPD, n (%)              | 30 (19.1)              | 19 (16.2)            | 11 (27.5)                     | 0.183    |
| Current smoker, n (%)    | 36 (22.3)              | 23 (18.7)            | 7 (17.5)                      | 0.167    |
| Ex-smoker, n (%)         | 34 (20.5)              | 38 (30.9)            | 14 (35)                       | 0.330    |
| **Medication**           |                        |                      |                               |          |
| Beta-blockers            | 105 (64)               | 80 (64.5)            | 25 (62.5)                     | 0.967    |
| ACE inhibitors/angiotensin receptor blockers | 129 (78.7)   | 99 (79.8)            | 30 (75)                       | 0.669    |
| MR antagonists           | 108 (65.9)             | 87 (70.2)            | 21 (52.5)                     | 0.063    |
| Glycosides               | 72 (43.9)              | 49 (39.5)            | 23 (57.5)                     | 0.070    |
| Loop diuretics           | 161 (98.2)             | 121 (97.6)           | 40 (100)                      | 0.753    |
| Nitrates                 | 15 (9.1)               | 9 (7.3)              | 6 (15)                        | 0.245    |

ACE, angiotensin-converting enzyme; COPD, chronic obstructive pulmonary disease; CT-proET1, C-terminal endothelin-1 precursor fragment; GFR, glomerular filtration rate; ICD/CRT, implantable cardioverter defibrillator/cardiac resynchronization therapy; IQR, interquartile range; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; MR-proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial natriuretic peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PWED, end-diastolic posterior wall; SD, standard deviation.

Data are presented as n (%), mean ± SD, or median [25th–75th percentiles].

*P < 0.05.

Table 2  Serial in-hospital changes of studied biomarkers

| Biomarker                  | Baseline (n = 164) | 24 h (n = 160) | 48 h (n = 155) | 72 h (n = 140) | Discharge (n = 153) |
|----------------------------|--------------------|----------------|----------------|----------------|---------------------|
| Copeptin (pmol/L)          | 31.4 [16.8–48.5]   | 27.2 [16.3–42.6] | 27.9 [15.3–40.5] | 27.1 [15.9–39.5] | 23.5 [14.8–36.1]    |
| NT-proBNP (pg/mL)          | 3894 [1605–11592]  | 3194 [1220–8426]** | 2505 [689–7720]** | 2698 [758–8424]** | 1808 [613–4259]**   |
| MR-proANP (pmol/L)         | 375.5 [220.4–599.6] | 355.1 [211.8–568.8]** | 340.5 [207.5–543.5]** | 328.2 [203.5–596.5]** | 308.9 [182.6–481.6]** |
| MR-proADM (nmol/L)         | 1.23 [0.85–2.02]   | 1.15 [0.81–1.87]* | 1.08 [0.77–1.71]** | 1.04 [0.75–1.73]** | 1.03 [0.76–1.49]**   |
| CT-proET1 (pmol/L)         | 122.7 [81.9–194.5] | 109 [78.3–175.8]** | 104.7 [75.2–155.6]** | 104.9 [75–155.6]** | 99.1 [73–142.7]**    |

*P < 0.05.

**P < 0.001.
The gain of additional measurement can be observed as early as 48 hours after inclusion (LR $\chi^2 = 19.08$, added $\chi^2 = 5.1$, $P = 0.024$). The significant added value of copeptin re-measurement after 48 h persisted even after adjustment for age, gender, and NYHA functional class (LR $\chi^2 = 27.31$, added $\chi^2 = 6.43$, $P = 0.011$).

Re-measurement of NT-proBNP after 48 h showed the highest predictive value (NT-pro BNP $\chi^2 = 14.23$, C-index = 0.650, $P < 0.001$). Patients with low NT-proBNP levels on admission and 48 h had the best prognosis. Patients with low biomarker levels at admission that increased after 48 h had an even worse prognosis than had patient with elevated levels at admission (see Figure 5). Biomarker assessment at discharge did not provide additional information.

Unlike that of copeptin and NT-proBNP, re-measurement of other investigated biomarkers (MR-proANP, MR-proADM, and CT-proET1) during hospital stay did not provide incremental value over a single determination at hospital admission (data not shown).

### Discussion

This is the largest sample of serial in-hospital measurements of novel biomarker in a typical sample of WHF patients during hospitalization. The mean ejection fraction of the patients in this study was ~34%, which can be considered moderately reduced compared with that of other acute decompensated HF studies.

Copeptin was the strongest predictor for all-cause mortality/hospitalization at 90 days. Addition of baseline copeptin levels to baseline NT-proBNP levels significantly improved its prognostic performance for 90 day outcome. The best time point for re-measurement was 72 h, showing that patients with persistently elevated copeptin had the worst prognosis at 3 months’ follow-up.

In line with our results, patients with WHF and elevated copeptin levels were at increased risk of 90 day mortality, readmissions, and emergency department visits. Additionally, Gegenhuber et al. demonstrated that increased levels of copeptin, BNP, MR-proANP, and MR-proADM of patients with WHF at admission independently indicated an increased risk of 1 year mortality. Another study that included 172 patients with chronic stable HF showed that copeptin was an excellent predictor of outcome during a median period

### Table 3

|         | NT-proBNP | MR-proANP | MR-proADM | CT-proET1 |
|---------|-----------|-----------|-----------|-----------|
| Copeptin| 0.54      | 0.56      | 0.56      | 0.50      |
| NT-proBNP| 0.84    | 0.48      | 0.53      |           |
| MR-proANP| 0.63    | 0.65      |           |           |
| MR-proADM| 0.90    |           |           |           |

CT-proET1, C-terminal endothelin-1 precursor fragment; MR-proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial natriuretic peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide.

Spearman’s coefficient of correlation ($P < 0.001$ for all correlations).

### Table 4

|         | Events | Model LR $\chi^2$ | d.f. | $P$-value | C-index | 95% CI   | HR (per IQR) | 95% CI   |
|---------|--------|------------------|------|-----------|---------|----------|-------------|----------|
| CT-proET1| 164    | 2.57             | 1    | 0.109     | 0.618   | [0.523, 0.714] | 1.32     | [0.91–1.92] |
| MR-proADM| 164    | 4.03             | 1    | 0.045     | 0.658   | [0.562, 0.753] | 1.33     | [0.98–1.82] |
| MR-proANP| 164    | 6.84             | 1    | 0.009     | 0.620   | [0.524, 0.716] | 1.76     | [1.15–2.69] |
| NT-proBNP| 164    | 9.60             | 1    | 0.002     | 0.641   | [0.55, 0.733]  | 2.08     | [1.27–3.40] |
| Copeptin| 164    | 13.98            | <0.001| 0.707     | 0.622   | [0.562, 0.792] | 2.02     | [1.44–2.84] |

CI, confidence interval; CT-proET1, C-terminal endothelin-1 precursor fragment; HR, hazard ratio; IQR, interquartile range; LR, likelihood ratio; MR-proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial natriuretic peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide.

ESC Heart Failure 2018; 5: 288–296
DOI: 10.1002/ehf2.12231
Similarly, copeptin levels predicted mortality in stable patients with chronic HF independently from clinical variables, including plasma sodium levels and loop diuretic doses. Even after a 13 year follow-up period, copeptin levels demonstrated a prognostic value for mortality risk in 470 elderly patients with HF. In the BACH (Biomarkers in Acute Heart Failure) study, in patients presenting to the emergency room with dyspnoea, elevated copeptin levels were associated with increased 90 day mortality, HF-related admission, and HF-related emergency department visits. Thus, current literature outlines the prognostic value of copeptin in patients with HF.

Another publication showed similarly to ours that adding copeptin to NT-proBNP improved its long-term prognostic performance for mortality in elderly patients with HF. Additionally, the combination of increased concentration of copeptin and NT-proBNP was found to be related with enhanced risk of all-cause mortality during a median period of 13 years in 470 elderly patients with symptoms of HF.
Another study showed that a decrease in NT-proBNP levels in patients with WHF was associated with better prognosis. Our study showed that repeated measurement of copeptin 72 h after admission may be advised for the improvement of risk stratification. Persistently elevated copeptin levels during hospitalization, from admission to 72 h, seem to be related with worse outcome. Despite the fact that a single measurement of a biomarker during the progression of a disease may predict the outcome, there is currently much interest in using serial biomarker measurements for monitoring the drug therapy response. One recent study evaluated copeptin variations during hospitalization and its prognostic significance in patients with dyspnoea at emergency departments. It demonstrated that dyspnoeic patients with high levels of copeptin at both hospital admission and discharge had significantly higher risk of developing events (death or rehospitalization) at 90 days. In line with our results, the authors demonstrated that there was a better 90 day prognosis in dyspnoeic patients with a higher decrease of copeptin from admission to discharge compared with patients who showed a lower decrease of copeptin. Additionally, this study showed that in both acute HF and non-acute HF patients, a great reduction of copeptin from admission to discharge is desirable and is linked to a better outcome. An increase in copeptin concentration between baseline and 1 month was associated with an increased risk of death and the composite cardiovascular endpoint in patient with HF after an acute myocardial infarction. Increases in copeptin and MR-proANP detected by serial measurements during follow-up in ambulatory patients with chronic HF appear to be common and predictive of increased risk of short-term events including death.

In contrast to these results, another study showed that a relative change of copeptin levels in patients after HF hospitalization (3 month follow-up vs. discharge value) did not contribute in risk stratification of these patients, because no pattern of improvement or of worsening added any prognostic information. This study included a cohort of stable HF patients undergoing treatment optimization. Similarly, another study with stable HF patients showed that change of copeptin at 3 months compared with that at baseline did not provide new prognostic value.

During an episode of WHF treatment, intervention rapidly resets neurohormonal values to their steady state. That is why serial measurements of biomarkers in the context of WHF may be more valuable than that in the context of chronic HF. For BNP and NT-proBNP, studies evaluating the influence of treatment on hormone concentrations have shown that therapeutic inhibition of the renin–angiotensin–aldosterone system decreases peptide levels, while beta-blockade results in an initial increase followed by a decline. To reap the full prognostic benefit of repeated measurements, a time frame has to be defined including the point at which re-measurement of specific biomarker may provide additional information. This is key for further studies on the efficacy of neurohormonal-guided therapy, which have failed to show benefit so far.

Limitation of the study

Major limitations of this study were the small sample of patients observed and short follow-up period. This resulted in a relatively small number of 90 day events.

Conclusions

Serial in-hospital measurements of copeptin levels among hypertensive HF patients provide additional prognostic values for all-cause mortality/hospitalizations, unlike those of other cardiac biomarkers (MR-proADM, MR-proANP, and CT-proET1). Patients with persistently elevated copeptin during the first 72 h after initial in-hospital evaluation had the worst prognosis at 3 months’ follow-up. Copeptin levels at hospital admission increased the prognostic value of NT-proBNP, the established biomarker in HF.

Conflict of interest

H.-D.D. reported receiving grant support from Thermo Fisher Scientific, Hennigsdorf, Germany.
Results from the MOLITOR study

Funding

This work was supported by Thermo Fisher Scientific, Hennigsdorf, Germany.

References

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kerber L, Lip GY, Moggioni AP, Parkhomenko A, Pieke BM, Papeschi BA, Rimmevik PK, Rutten FH, Zwijter J, Severofic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Cecconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knutti J, Kolb P, McDonagh T, Moulin C, Pologe BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Valjannian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P, ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803–869.

2. Maisel A, Mueller C, Nowak RM, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Cleton-P, Filippatos GS, Di Somma S, Anand I, Ng LL, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Hartmann O, von Haehling S, Bergmann A, Morgenbenthaler NG, Anker SD. Mid-regional proadrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 2010 May; 12: 484–491.

3. Bakar Y, May CN, Ramanchandra R. Role of endothelin-1 in mediating changes in cardiac sympathetic nerve activity in heart failure. Am J Physiol Regul Integr Comp Physiol 2016 Jan 1; 310: R94–R99.

4. Lindberg S, Jensen JS, Pedersen SH, Galatius S, Goetze JP, Mogelvang R. MR-proANP improves prediction of mortality and cardiovascular events in patients with STEMI. Eur J Prev Cardiol 2015 Jun; 22: 693–700.

5. Zografas T, Kastrissis D. Natriuretic peptides as predictors of atrial fibrillation recurrence following electrical cardioversion. Arrhythm Electrophysiol Rev 2013 Nov; 2: 109–114.

6. Yang K, Yang T, Sivri N, Yetkin E. Peptide of heart failure and cardiac cachexia. J Mol Med 2014 Dec 22; 15: 23878–23896.
of copeptin, a stable peptide derived from the precursor of vasopressin. *Clin Chem* 2006; 52: 112–119.

22. Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. *Circulation* 2004; 110: 2168–2174.

23. Miller WL, Hartman KA, Burritt MF, Grill DE, Rodeheffer RJ, Burnett JC Jr, Jaffe AS. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. *Circulation* 2007; 116: 249–257.

24. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit Y. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. *J Am Coll Cardiol* 2007; 49: 1733–1739.

25. Troughton RW, Richards AM. Outpatient monitoring and treatment of chronic heart failure guided by amino-terminal pro-B-type natriuretic peptide measurement. *Am J Cardiol* 2008; 101: 72–75.

26. Vetrone F, Santarelli S, Russo V, Lalle I, De Berardinis B, Magrini L, Di Stasio E, Salerno G, Cardelli P, Piccoli A, Codognotto M, Mion MM, Plebani M, Vettore G, Castello LM, Avanzi GC, Di Somma S. Copeptin decrease from admission to discharge has favorable prognostic value for 90-day events in patients admitted with dyspnea. *Clin Chem Lab Med* 2014; 52: 1457–1464.

27. Voors AA, van Haehling S, Anker SD, Hilleghe HL, Struck J, Hartmann O, Bergmann A, Squire I, van Veldhuisen DJ, Dickstein K, OPTIMAAL Investigators. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. *Eur Heart J* 2009; 30: 1187–1194.

28. Miller WL, Hartman KA, Grill DE, Struck J, Bergmann A, Jaffe AS. Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure. *Heart* 2012; 98: 389–394.

29. Neuhold S, Huelsmann M, Strunk G, Struck J, Adlbrecht C, Gouya G, Elhenicky M, Pacher R. Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy. *Clin Chem* 2010; 56: 121–126.

30. Masson S, Latini R, Carbonieri E, Moretti L, Rossi MG, Ciricugno S, Milani V, Marchioli R, Struck J, Bergmann A, Maggioni AP, Tognoni G, Tavazzi L, Investigators GISSI-HF. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. *Eur J Heart Fail* 2010; 12: 338–347.

31. Loncar G, von Haehling S, Tahirovic S, Putnikovic B, Edelmann F, Wachter R, Dimkovic S, Waagstein F, Gelbrich G, Düngen HD. Effect of beta blockade on natriuretic peptides and copeptin in elderly patients with heart failure and preserved or reduced ejection fraction: results from the CIBIS-ELD trial. *Clin Biochem* 2010; 45: 117–122.

32. Anand IS, Fisher LD, Chiang YT, Latin R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN, Investigators V-HFT. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). *Circulation* 2003; 107: 1278–1283.

33. Rousseau MF, Gurné O, Duprez D, Van Mieghem W, Robert A, Ahn S, Galanti L, Ketelslegers JM, Belgian RALES Investigators. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. *J Am Coll Cardiol* 2002; 40: 1596–1601.